The idea in plain English
A stent is a small mesh tube placed inside a blood vessel. Normally it is passive: it simply holds the vessel open. An active stent adds electronics, so the device can sense what passes through it and respond.
The best-known example comes from oncologist Dr Azra Raza of Columbia University. She describes a device called the Stentinel (sentinel + stent), developed with biomedical engineers at Columbia. Her descriptions say it would sit in a vein, continuously scan the bloodstream for the earliest cancer cells and biomarkers, and could be programmed to destroy them with an electrical pulse.
Why the potential is exciting
Catching disease at the very start
Dr Raza’s “first cell” approach aims to find and remove cancer before it multiplies, instead of chasing advanced disease. She describes detection at “Stage Negative One”.
Continuous watching, not occasional tests
A stent in the bloodstream could monitor around the clock, rather than relying on a scan or blood test at a single moment.
Detection and response in one device
The concept combines sensing with a built-in electrical response, so the same implant that finds a suspect cell could act on it.
Built on a familiar medical device
Stents are routine in medicine. Starting from one may help with safety thinking and manufacturing, though a new electronic version would still need its own evidence and approval.
Potential for low cost and wide access
Dr Raza has said the aim is for the stent to be affordable, quoting a figure of about $80, so that it is not a luxury for the rich.
A wider field is forming
Other teams are building stents with wireless sensors for blood pressure and flow, and “electronic blood vessels” that carry circuitry. Electrical pulses are already used to destroy tumour cells in a technique called irreversible electroporation. A far older patent describes electrodes in the veins to treat blood-borne viruses.
A realistic view. The Stentinel is a development-stage concept, not an approved treatment or a cure for cancer. Published reports describe a target of availability around 2028 and a biological rationale based on unusually large circulating cells. That finding does not by itself show the device can detect or eliminate cancer. Dr Raza’s work concerns cancer cells; it is not specifically about bacteria or viruses.
This page is a marketing summary prepared from public sources. It is not medical advice or a statement about any product’s safety or effectiveness.
Inside the name: activ + stent
Look closely at activstent and the name splits in two:
- activ = active. A short, modern spelling that signals a powered, sensing, responsive stent rather than a passive one.
- stent = the device. The ending names the product in a single word.
Why the right domain name matters
In medical devices, trust is everything. Clinicians, investors, partners and regulators look at a company’s name and web address before they read anything else. A weak or confusing address makes a serious technology look improvised.
- It describes the category. “Activ” signals powered and responsive, and “stent” names the device. Visitors grasp it quickly.
- It is short and distinctive. Ten letters, easy to say aloud, with a spelling that stands out from generic “active stent” wording and is easier to claim as a brand.
- It builds credibility. An exact, professional .com suggests a well-established venture.
- It works as a brand foundation. A company, product line or platform name can grow from it, with matching professional email addresses.
- It helps people find you. People searching for active or electronic stents are more likely to remember and reach a name that says so.
- It avoids a costly rebrand. Changing names later means new materials, lost search standing and confused partners.
- It protects your space. Owning the name keeps a competitor from taking it.
Who it suits
Medical device manufacturers, start-ups and university spin-outs working on electronic or sensing stents, cardiovascular and oncology technology companies, and investors building a brand around active implants.
ActivStent.com is available. To make an offer or ask about leasing, please enquire through URLease.com.
Independent listing. Not affiliated with, or endorsed by, Dr Azra Raza, Columbia University or any company named on this page. Buyers should carry out their own trademark and due-diligence checks.
Sources
- Dr Azra Raza, “Healing, hope, and the human spirit”, Sapan News, June 2025: sapannews.com
- “Paradigm shift needed in cancer research”, Sapan News, 2026 (cost and 2028 target): sapannews.com
- “The Early Battle”, Aldia News (giant circulating cells; not a cure): aldianews.com
- Interview with Azra Raza, Thoughtforms Life Podcast (Columbia engineers Sam Sia and Ken Shepherd): thoughtforms-life.aipodcast.ing
- Herbert et al., wireless vascular electronics, Science Advances, 2022: summary
- IEEE Spectrum, electronic blood vessels: spectrum.ieee.org
- US Patent 6,539,252, blood-borne pathogen treatment: USPTO